# [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

> **NCT02562989** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 13 (actual)

## Conditions studied

- Alzheimer's Disease
- Amnestic Mild Cognitive Impairment

## Interventions

- **DRUG:** [18F]MK-6240, ~185 MBq
- **DRUG:** [18F]MK-6240, ~160 MBq

## Key facts

- **NCT ID:** NCT02562989
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-19
- **Primary completion:** 2016-12-27
- **Final completion:** 2016-12-27
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562989, "[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02562989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*